T
Thomas A. Moss
Researcher at AstraZeneca
Publications - 27
Citations - 541
Thomas A. Moss is an academic researcher from AstraZeneca. The author has contributed to research in topics: Catalysis & Alkylation. The author has an hindex of 11, co-authored 24 publications receiving 415 citations. Previous affiliations of Thomas A. Moss include University of Oxford & University of Manchester.
Papers
More filters
Journal ArticleDOI
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-Fluoro-2-Methylpropyl)-3-Methyl-2, 3,4,9-Tetrahydro-1H-Pyrido[3,4-B]Indol-1-Yl)Phenyl)Acrylic Acid (Azd9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.
Chris De Savi,Robert Hugh Bradbury,Alfred A. Rabow,Richard A. Norman,Camila de Almeida,David M. Andrews,Peter Ballard,David Buttar,Rowena Callis,Gordon S. Currie,Jon Curwen,Christopher D. Davies,Craig S. Donald,Lyman Feron,H. Gingell,Steven C. Glossop,Barry R. Hayter,Syeed Hussain,Galith Karoutchi,Scott G. Lamont,Philip A. MacFaul,Thomas A. Moss,Stuart E. Pearson,Michael Tonge,Graeme Walker,Hazel M. Weir,Zena Wilson +26 more
TL;DR: The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equivalent potency and preclinical pharmacology to the intramuscular SERD fulvestrant is described.
Journal ArticleDOI
Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum.
Nicholas A. Malmquist,Thomas A. Moss,Salah Mecheri,Salah Mecheri,Artur Scherf,Artur Scherf,Matthew J. Fuchter +6 more
TL;DR: The data position histone lysine methyltransferases as a previously unrecognized target class, and BIX-01294 as a promising lead compound, in a presently unexploited avenue for antimalarial drug discovery targeting multiple life-cycle stages.
Journal ArticleDOI
Catalytic Enantio- and Diastereoselective Alkylations with Cyclic Sulfamidates
TL;DR: Several natural products containing the aminoethylene and aminopropylene scaffolds attached to a quaternary stereocenter have been isolated.
Journal ArticleDOI
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
James S. Scott,Thomas A. Moss,Amber Balazs,Barlaam Bernard Christophe,Jason Breed,Rodrigo J. Carbajo,Elisabetta Chiarparin,Paul R. J. Davey,Oona Delpuech,Stephen Fawell,David I Fisher,Sladjana Gagrica,Eric Gangl,Tyler Grebe,Ryan Greenwood,Sudhir M. Hande,Holia Hatoum-Mokdad,Kara Herlihy,Samantha Jayne Hughes,Thomas Anthony Hunt,Hoan Huynh,Sophie L. M. Janbon,Tony Johnson,Stefan Kavanagh,Teresa Klinowska,Mandy Lawson,Andrew Lister,Stacey Marden,Dermot F. McGinnity,Christopher J. Morrow,J. Willem M. Nissink,Daniel Hillebrand O'donovan,Bo Peng,Radoslaw Polanski,Darren Stead,Stephen Stokes,Kumar Thakur,Scott Throner,Michael J. Tucker,Jeffrey G. Varnes,Haixia Wang,David Matthew Wilson,Dedong Wu,Ye Wu,Bin Yang,Wenzhan Yang +45 more
TL;DR: This compound was demonstrated to be a highly potent SERD which showed a comparable pharmacological profile to fulvestrant in its ability to degrade ER in both MCF-7 and CAMA-1 cell lines.
Journal ArticleDOI
Catalytic Asymmetric Alkylation Reactions for the Construction of Protected Ethylene‐Amino and Propylene‐Amino Motifs Attached to Quaternary Stereocentres
TL;DR: An efficient catalytic and stereoselective method for the direct construction of protected ethylene-amino and propylene-AMino scaffolds attached to quaternary stereocentres and the utility of the products have been demonstrated in the synthesis of useful heterocycles and compounds bearing structural components of natural products.